Aurinia Pharmaceuticals (AUPH) Profit After Tax (2019 - 2026)

Aurinia Pharmaceuticals has reported Profit After Tax for 8 years, with the latest figure at $34.4 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 47.17% year-over-year to $34.4 million; the trailing twelve-month figure through Mar 2026 stood at $298.2 million (up 648.43% YoY), and the FY2025 full-year result was $287.2 million, up 4893.08% from the prior year.
• Profit After Tax for Q1 2026 stood at $34.4 million, down from $210.8 million in the prior quarter.
• The five-year high for Profit After Tax was $210.8 million in Q4 2025, with the low at -$37.6 million in Q1 2022.
• Historically, Profit After Tax has averaged $8.3 million across 5 years, with a median of -$9.0 million in 2022.
• Annual changes were most pronounced in 2023 — Profit After Tax plunged 49.59% — and 2025, when it surged 14651.15%.
• Aurinia Pharmaceuticals' Profit After Tax stood at -$26.0 million in 2022, then retreated by 3.18% to -$26.9 million in 2023, then surged by 105.32% to $1.4 million in 2024, then surged by 14651.15% to $210.8 million in 2025, then tumbled by 83.7% to $34.4 million in 2026.
• The last three Profit After Tax figures came in at $34.4 million (Q1 2026), $210.8 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.